Vol 9, No 1 (February 08, 2018): Journal of Gastrointestinal Oncology (Evolving Role of Immune-oncology Therapeutics in GI Malignancies)

Original Article

A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma
Annika L. Windon, Arturo Loaiza-Bonilla, Christopher E. Jensen, Michael Randall, Jennifer J. D. Morrissette, Stuti G. Shroff
Advanced age does not increase morbidity in pancreaticoduodenectomy
Guilherme Naccache Namur, Anna Carolina Batista Dantas, Ricardo Jureidini, Thiago Costa Ribeiro, Ulysses Ribeiro Junior, Estela Figueira, Ivan Cecconello, Telesforo Bacchella
Cachexia, and not obesity, prior to pancreatic cancer diagnosis worsens survival and is negated by chemotherapy
Andrew E. Hendifar, Jonathan I. Chang, Brian Z. Huang, Richard Tuli, Bechien U. Wu
Impact of sarcopenia in borderline resectable and locally advanced pancreatic cancer patients receiving stereotactic body radiation therapy
William H. Jin, Eric A. Mellon, Jessica M. Frakes, Gilbert Z. Murimwa, Pamela J. Hodul, Jose M. Pimiento, Mokenge P. Malafa, Sarah E. Hoffe
Comparison of perioperative chemotherapy with adjuvant chemoradiotherapy for resectable gastric cancer: findings from a population-based study
Brice Jabo, Matthew J. Selleck, John W. Morgan, Sharon S. Lum, Khaled A. Bahjri, Mayada Aljehani, Carlos A. Garberoglio, Mark E. Reeves, Jukes P. Namm, Naveenraj L. Solomon, Fabrizio Luca, Crickett Dyke, Maheswari Senthil
Evaluation of altered expression of miR-9 and miR-106a as an early diagnostic approach in gastric cancer
Khadije Shirmohammadi, Sareh Sohrabi, Zahra Jafarzadeh Samani, Hosein Effatpanah, Reza Yadegarazari, Massoud Saidijam
Establishment and validation of prognostic nomograms in first- line metastatic gastric cancer patients
Yukiya Narita, Shigenori Kadowaki, Isao Oze, Yosuke Kito, Takeshi Kawakami, Nozomu Machida, Hiroya Taniguchi, Takashi Ura, Masashi Ando, Seiji Ito, Masahiro Tajika, Yasushi Yatabe, Hirofumi Yasui, Kei Muro
Predictors of overall survival after surgery in gastric cancer patients from a Latin-American country
Eugenia Cordero-García, Allan Ramos-Esquivel, Warner Alpízar-Alpízar
Complete pathologic response is independent of the timing of esophagectomy following neoadjuvant chemoradiation for esophageal cancer
Smit Singla, Emmanuel Gabriel, Raed Alnaji, William Du, Kristopher Attwood, Hector Nava, Steven N. Hochwald, Moshim Kukar
Radiation dose in neoadjuvant chemoradiation therapy for esophageal cancer: patterns of care and outcomes from the National Cancer Data Base
Waqar Haque, Vivek Verma, E. Brian Butler, Bin S. Teh
Colorectal lymphoma in Mexico: clinico-pathological and survival analysis
Everardo Jaime- Andrade, Leonardo S. Lino- Silva, Rosa A. Salcedo- Hernández, César Zepeda- Najar
Age-related rates of colorectal cancer and the factors associated with overall survival
Emmanuel Gabriel, Kristopher Attwood, Eisar Al-Sukhni, Deborah Erwin, Patrick Boland, Steven Nurkin
Investigation of targetable predictive and prognostic markers in gallbladder carcinoma
Azfar Neyaz, Nuzhat Husain, Sameer Gupta, Swati Kumari, Aditi Arora, Namrata Puneet Awasthi, Kiran Preet Malhotra, Sanjeev Misra
Disparities in resection of hepatic metastases in colon cancer
Madalyn G. Neuwirth, Andrew J. Epstein, Giorgos C. Karakousis, Ronac Mamtani, E. Carter Paulson

Short Communication

The nab-paclitaxel/gemcitabine regimen for patients with refractory advanced pancreatic adenocarcinoma
Sofia Palacio, Peter J. Hosein, Isildinha Reis, Ikechukwu I. Akunyili, Vinicius Ernani, Terri Pollack, Jessica Macintyre, Maria H. Restrepo, Jaime R. Merchan, Caio M. Rocha Lima

Editorial on Evolving Role of Immune-oncology Therapeutics in GI Malignancies1

The coming of age: immunotherapy in gastrointestinal malignancies
Devalingam Mahalingam

Disclosure:

1. The series “Evolving Role of Immune-oncology Therapeutics in GI Malignancies” was commissioned by the Editorial office, Journal of Gastrointestinal Oncology without any sponsorship or funding. Devalingam Mahalingam served as the unpaid Guest Editor for the series.